Understanding and managing ultra high-risk chronic lymphocytic leukemia.
about
Idelalisib for the treatment of chronic lymphocytic leukemiaSelective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemiaMutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractorinessComplement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cGeneralized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia.Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibitionChronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomesSafety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 studyChoosing first-line therapy for chronic lymphocytic leukemia.TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden.Therapeutic antibodies against cancer.Utilisation of nanoparticle technology in cancer chemoresistance.HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathwayRisk categories and refractory CLL in the era of chemoimmunotherapy.Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.Autophagy contributes to apoptosis in A20 and EL4 lymphoma cells treated with fluvastatinPatients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis.A Novel Assay for the Identification of NOTCH1 PEST Domain Mutations in Chronic Lymphocytic Leukemia.Involvement of memory T-cells in the pathophysiology of chronic lymphocytic leukemia.Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.Treatment of relapsed or refractory chronic lymphocytic leukemia.Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia.The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia.Molecular genetics of high-risk chronic lymphocytic leukemia.How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?Shifting paradigms in the treatment of chronic lymphocytic leukemia.The molecular pathogenesis of chronic lymphocytic leukaemia.Metadherin contributes to the pathogenesis of chronic lymphocytic leukemia partially through Wnt/β-catenin pathway.Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia.Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study.The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1.Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter.Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders.Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia
P2860
Q27015826-96EF11E5-A1F6-4D00-8E09-DAD2D83B45B0Q27674083-03BDDEE3-9C7C-4454-BC4D-99A69A319756Q27851685-F68CD283-E870-45FB-A630-9C37DE82EF4CQ29013141-5A8E8B93-0416-4770-A1E4-B70997FA69E5Q30356145-1D93DC5D-4CF8-458A-82E4-C3952E9218ECQ30408922-6642760B-E977-4C16-92AD-2AF43A837085Q33399400-852FDAC0-D011-4523-B67A-236F8135BCA7Q33407258-AC800E7C-7013-4BB6-997A-4D3C32B1F2A1Q33558148-9D2CE389-5C31-483A-9B41-6795E7D403F7Q34240404-D197DA75-36A4-4A8B-A23B-559BD1C61B29Q35124844-2DBC821D-0DE2-425C-91FB-68C488123D3FQ35128888-003E1836-C2F4-4848-94CD-83F7A865E83FQ35407650-B8139274-49C8-4808-83BB-1A5C9B348D70Q35569491-96FC9B93-6790-4448-82AD-5BFEC484EE06Q35676442-8AF6F320-4071-4236-B5CE-F9DAEAC6629AQ35908498-8EFCA6F8-C3B5-4E58-B70A-EA9AE35FE0BFQ36421258-E0396854-8CA6-4406-872B-9A582AECC6ADQ37073682-2D235190-52BF-4EC5-9F11-6A8CB7C62A7BQ37141887-057F5E7D-E127-49E0-B816-4AED9E0E75F3Q37188389-66F87CF3-0AF5-4DF4-A319-0FB075640A7FQ37320402-8236CE54-9638-4A91-AACD-AFBA2AD11AC4Q37532952-20238EEF-4789-48CF-BF9E-B90BF7CF2476Q37542431-2DB8E3EE-3A5D-43FA-A16C-026FBA26A250Q37628625-69D9C14B-4CCC-40A3-83A2-C4F8BF73E021Q37958036-0C48E612-6D02-444C-9275-F70D7AD2418FQ37964916-62077555-BFB7-4823-8833-733210DC3D8CQ37978967-83447C70-CB8F-4289-9B51-E4CD89255A1EQ38012165-FB1068DB-825B-4B9B-A981-F3D427E39EB7Q38065304-5D6C504A-2A02-4C00-A6D9-54917130450AQ38340201-50CC8A82-0606-436D-BC68-7BE08DC4DCB4Q38357127-EF587F73-DC03-4E8F-BEBA-6D4F180AA7ECQ38748645-69975B60-2A19-4CC6-BB39-69EDBAB8A1AEQ38921580-983E8299-4D2F-498F-97D7-1EE9498870C8Q39034623-C69A7AC1-4459-4B3F-9FFC-0FFF0D49B3B7Q39996013-E7211EC0-28E9-42E8-8BB7-63F4FBA7F655Q40817325-DA67AD94-2492-4446-9174-8AB073410468Q42593100-B5B32FAD-0E3E-40C8-B783-62C6520D7CE3Q43043031-47D5F6F1-4DAF-44FB-9824-0DDA89476493Q48505196-66AFD893-3043-4710-8EAA-045F686B3641Q57229768-114CBF06-8604-48AC-886C-A46E9152D84B
P2860
Understanding and managing ultra high-risk chronic lymphocytic leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Understanding and managing ultra high-risk chronic lymphocytic leukemia.
@en
Understanding and managing ultra high-risk chronic lymphocytic leukemia.
@nl
type
label
Understanding and managing ultra high-risk chronic lymphocytic leukemia.
@en
Understanding and managing ultra high-risk chronic lymphocytic leukemia.
@nl
prefLabel
Understanding and managing ultra high-risk chronic lymphocytic leukemia.
@en
Understanding and managing ultra high-risk chronic lymphocytic leukemia.
@nl
P1476
Understanding and managing ultra high-risk chronic lymphocytic leukemia.
@en
P304
P356
10.1182/ASHEDUCATION-2010.1.481
P577
2010-01-01T00:00:00Z